KR20200096904A - 호흡기 세포융합 바이러스(rsv) 감염의 예방을 위한 백신 및 백신의 제조 및 사용 방법 - Google Patents

호흡기 세포융합 바이러스(rsv) 감염의 예방을 위한 백신 및 백신의 제조 및 사용 방법 Download PDF

Info

Publication number
KR20200096904A
KR20200096904A KR1020207010971A KR20207010971A KR20200096904A KR 20200096904 A KR20200096904 A KR 20200096904A KR 1020207010971 A KR1020207010971 A KR 1020207010971A KR 20207010971 A KR20207010971 A KR 20207010971A KR 20200096904 A KR20200096904 A KR 20200096904A
Authority
KR
South Korea
Prior art keywords
rsv
protein
composition
rvsv
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207010971A
Other languages
English (en)
Korean (ko)
Inventor
스테판 니오베이스크
바사바라지 빈자와다기
지안롱 리
마크 피플스
Original Assignee
오하이오 스테이트 이노베이션 파운데이션
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오하이오 스테이트 이노베이션 파운데이션, 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 filed Critical 오하이오 스테이트 이노베이션 파운데이션
Publication of KR20200096904A publication Critical patent/KR20200096904A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207010971A 2017-09-15 2018-09-14 호흡기 세포융합 바이러스(rsv) 감염의 예방을 위한 백신 및 백신의 제조 및 사용 방법 Ceased KR20200096904A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762559167P 2017-09-15 2017-09-15
US62/559,167 2017-09-15
PCT/US2018/051054 WO2019055768A1 (en) 2017-09-15 2018-09-14 VACCINES AND METHODS OF MAKING AND USING VACCINES FOR THE PREVENTION OF SYNCYTIAL RESPIRATORY VIRUS (RSV) INFECTIONS

Publications (1)

Publication Number Publication Date
KR20200096904A true KR20200096904A (ko) 2020-08-14

Family

ID=65723867

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207010971A Ceased KR20200096904A (ko) 2017-09-15 2018-09-14 호흡기 세포융합 바이러스(rsv) 감염의 예방을 위한 백신 및 백신의 제조 및 사용 방법

Country Status (8)

Country Link
US (1) US20200276297A1 (enExample)
EP (1) EP3681523A4 (enExample)
JP (1) JP2020534284A (enExample)
KR (1) KR20200096904A (enExample)
CN (1) CN111344008A (enExample)
AU (1) AU2018331467A1 (enExample)
CA (1) CA3075990A1 (enExample)
WO (1) WO2019055768A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023055154A1 (ko) * 2021-09-29 2023-04-06 에스케이바이오사이언스 주식회사 재조합된 약독화 rsv 생백신 및 이를 제조하는 방법

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7657727B2 (ja) 2019-04-02 2025-04-07 サノフイ 抗原性多量体呼吸器合胞体ウイルスポリペプチド
CN112226450B (zh) * 2020-08-25 2022-10-14 北京交通大学 一种共表达呼吸道合胞病毒融合前蛋白和黏附糖蛋白的复制缺陷型腺病毒载体疫苗
KR102806300B1 (ko) * 2023-01-13 2025-05-14 클립스비엔씨 주식회사 호흡기 신시치아 바이러스 변이체를 포함하는 호흡기 신시치아 바이러스 백신용 융합단백질 및 이의 제조방법
CN118930654A (zh) * 2023-05-12 2024-11-12 中国科学院微生物研究所 一种呼吸道合胞病毒抗原制备方法和应用
CN117720628A (zh) * 2023-10-12 2024-03-19 中国科学院微生物研究所 一种呼吸道合胞病毒二价抗原制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1224462A (zh) * 1996-07-15 1999-07-28 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
IL145797A0 (en) * 1999-04-13 2002-07-25 Government Of The Us Dept Of H Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
AU2001264824A1 (en) * 2000-06-01 2001-12-11 St. Jude Children's Research Hospital Vaccine and gene therapy vector and methods of use thereof
US20050048030A1 (en) * 2001-09-28 2005-03-03 Raymond Pickles Paramyxoviruses as gene transfer vectors to lung cells
TWI344991B (en) * 2002-02-21 2011-07-11 Medimmune Vaccines Inc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
EP1527087B2 (en) * 2002-07-26 2013-07-17 Her Majesty, The Queen in Right of Canada, as Represented by The Minister of Health Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers
WO2004113517A2 (en) * 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
US7585667B2 (en) * 2003-06-13 2009-09-08 The United States Of America As Represented By The Department Of Health And Human Services Negative strand RNA virus replicon
EP1756287B1 (en) * 2004-04-09 2015-02-25 Wyeth LLC Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
WO2008133663A2 (en) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
US20090092635A1 (en) * 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
US20090162321A1 (en) * 2007-12-20 2009-06-25 Wyeth Methods for packaging propagation-defective vesicular stomatitis virus vectors using a stable cell line that expresses g protein
BRPI0921424A2 (pt) * 2008-11-05 2016-01-05 Merck Sharp & Dohme vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.
AU2015225553B2 (en) * 2014-03-01 2020-02-27 Profectus Biosciences, Inc. Recombinant Isfahan viral vectors
EP3154576A1 (en) * 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023055154A1 (ko) * 2021-09-29 2023-04-06 에스케이바이오사이언스 주식회사 재조합된 약독화 rsv 생백신 및 이를 제조하는 방법

Also Published As

Publication number Publication date
EP3681523A1 (en) 2020-07-22
WO2019055768A1 (en) 2019-03-21
CN111344008A (zh) 2020-06-26
US20200276297A1 (en) 2020-09-03
CA3075990A1 (en) 2019-03-21
EP3681523A4 (en) 2021-12-29
AU2018331467A1 (en) 2020-04-30
JP2020534284A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
US11975067B2 (en) Coronavirus disease (COVID-19) vaccine
CN111344008A (zh) 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
DK2370099T3 (en) Rsv f modified proteins and methods of their use
US11103576B1 (en) Measles virus vaccine expressing SARS-COV-2 protein(s)
KR20100109933A (ko) 재조합 ｒｓｖ 항원
CN102317308A (zh) 类病毒组合物颗粒及其使用方法
KR20150138184A (ko) 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
EP3049107A1 (en) Self-assembled nanoparticle vaccines
US20230174588A1 (en) A vaccine against sars-cov-2 and preparation thereof
US11576960B2 (en) Respiratory syncytial virus (RSV) vaccines
JP2023093566A (ja) Ｒｓｖ ｇを発現する組換えキメラウシ／ヒトパラインフルエンザウイルス３およびその使用法
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
US20230310585A1 (en) Vaccine for viral pathogens
CN103068985A (zh) 抗狂犬病的广谱狂犬病病毒属病毒疫苗
US20230285541A1 (en) Methods and compositions for increasing immunity against coronaviruses
KR20230005814A (ko) Cpg-어쥬번트된 sars-cov-2 바이러스 백신
US20220370600A1 (en) Multigenic mva-sars-cov-2 vaccine
CN117599160A (zh) 狂犬病疫苗免疫原组合物
HK40029686A (en) Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
US20230285542A1 (en) Coronavirus Vaccine
US20100172925A1 (en) Hla-a2-restricted t-cell epitopes of the respiratory syncytial virus fusion protein as peptide-based vaccines
JP2024518565A (ja) 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200416

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210903

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240408

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240625

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D